Tamoxifen (TAM; a selective estrogen receptor modulator), which has so far been used mainly as an adjuvant therapeutic in breast cancer, in recent preclinical studies has shown the potential to alleviate ovarian side effects of cancer treatment [8–10]. The gene discussed is ESR1; the disease is cancer.